Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapy for bronchopulmonary dysplasia - Medipost

Next Previous
Drug Profile

Mesenchymal stem cell therapy for bronchopulmonary dysplasia - Medipost

Alternative Names: Human umbilical cord blood-derived mesenchymal stem cells - Medipost; Pneumostem

Latest Information Update: 22 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medipost
  • Developer Medipost; Samsung Medical Center
  • Class Antidementias; Mesenchymal stem cell therapies; Neural stem cell therapies; Neuroprotectants
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia
  • New Molecular Entity No
  • Available For Licensing Yes - Bronchopulmonary dysplasia

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia; Haemorrhage

Most Recent Events

  • 22 Jul 2022 Phase-II development in Bronchopulmonary dysplasia (In infants, In children) is ongoing in South Korea (Intratracheal) (NCT04003857)
  • 01 Mar 2020 Medipost completes a follow-up phase II clinical trial for Bronchopulmonary dysplasia (In infants) in South Korea (Intratracheal) (NCT01897987)
  • 05 Jul 2019 Phase-II clinical trials in Bronchopulmonary dysplasia (In infants, In children) in South Korea (Intratracheal) (NCT04003857)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top